UK ATMP clinical research picture remains positive despite challenging global environment

Published on January 19, 2023

In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.

Continue reading on website
Other news

China approves Bio-Thera Solutions' biosimilar to Actemra

January 19, 2023
The China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra (tocilizumab), in China.

Resilience to expand global footprint, collaborating on first GMP biopharma facility in UAE

January 19, 2023
National Resilience has secured an equity investment from Mubadala, an Abu Dhabi sovereign investor. The amount was not disclosed.